Sensitivity of Imaging Modalities to Biochemical Recurrence in Prostate Cancer 

Dr Munir Ghesani reviews and comments on data regarding the sensitivity of imaging modalities in detecting biochemical recurrence in prostate cancer. 

FDA authorizes trial of novel PSMA theranostics in mCRPC

The SECURE trial is exploring the PSMA PET imaging product 64Cu-SAR-bisPSMA and the PSMA targeted therapy 67Cu-SAR-bisPSMA.

Studies spotlight misinformation in YouTube bladder and prostate cancer videos

“Our findings highlight an urgent need for more accurate, patient-friendly social media content,” says Dr. Stacy Loeb.